Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

No-Freeze skin tag remover tested in 200 adults

NCT ID NCT06463613

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a mechanical device that removes skin tags by cutting off their blood supply with a silicone band. It aims to be a less invasive option than freezing or burning. The study involves 200 adults with at least one skin tag between 4 and 6 millimeters wide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults at least 22 years of age. 2. Must be able to understand, speak, and read English sufficiently for completion of the trial. 3. Subject has at least one skin tag meeting ALL of the following requirements: 1. no previous attempts to remove the skin tag(s) of investigation, including skin tags that were treated in a previous version of this protocol 2. measuring between 4mm and 6mm at the base. Skin tags measuring larger than 6mm can be rounded down based on investigator's discretion. 3. not located around the eye, on the eyelid, or in the groin area 4. if treating two tags, only one may be located in axilla 5. free of any active skin infection \& area to treat tag has no severe eczema 6. located in an area where participant can take a self-taken photo 7. does not, in the opinion of the Investigator, require an evaluation by pathology at the time of screening 4. Subject has access to the internet via smartphone to complete the eDiary Exclusion Criteria: 1. Significant medical condition or other circumstance which, in the opinion of the Investigator, would preclude compliance with the protocol, adequate cooperation in the trial or providing informed consent, or may prevent the subject from safely participating in the trial 2. Any prior history of skin-related cancer 3. Subject states that they are currently pregnant or intending to become pregnant during the course of the study 4. Has an allergy to latex 5. Current diagnosis of a bleeding disorder included but not limited to Hemophilia or Von Willebrand disease 6. Currently being treated with blood thinners (use of 81 mg of Aspirin is not exclusionary) 7. Currently being treated with topical steroids at site of skin tag of interest or oral steroids 8. Currently immunocompromised by conditions such as diabetes (either Types 1 or 2, regardless of level of control) or receiving immunosuppressant therapy 9. Current MRSA infection 10. Diagnosis or any history of keloid or hypertrophic scarring 11. Current or recent participation within the last 30 days in another interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Achrochordon are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Center for Dermatology Clinical Research, Inc.

    Fremont, California, 94538, United States